Citius Pharmaceuticals (CTXR) Total Current Liabilities (2011 - 2026)
Citius Pharmaceuticals' (CTXR) quarterly Total Current Liabilities came in at $55.0 million in Q1 2026, up 10.3% YoY from $49.9 million in Q1 2025, and up 43.99% on a QoQ basis from $38.2 million in Q4 2025.
Citius Pharmaceuticals (CTXR) Total Current Liabilities (2011 - 2026) Analysis & Trends
Citius Pharmaceuticals (CTXR) has 16 years of Total Current Liabilities data on file, last reported at $55.0 million in Q1 2026.
- Quarterly Total Current Liabilities rose 10.3% year-over-year to $55.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $55.0 million (up 10.3% YoY) and the FY2025 annual result came in at $44.9 million, up 25.41% from the prior year.
- Total Current Liabilities advanced to $55.0 million in Q1 2026, from $38.2 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $55.0 million in Q1 2026 to a low of $4.0 million in Q1 2022.
- A 5-year average of $21.7 million and a median of $5.8 million in 2023 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Current Liabilities plunged 38.2% — and 2025, when it surged 1148.59%.
- Tracing CTXR's Total Current Liabilities over 5 years: stood at $4.5 million in 2022, then grew by 22.96% to $5.6 million in 2023, then soared by 703.14% to $44.8 million in 2024, then fell by 14.73% to $38.2 million in 2025, then soared by 43.99% to $55.0 million in 2026.
- The last three Total Current Liabilities figures came in at $55.0 million (Q1 2026), $38.2 million (Q4 2025), and $44.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 86.29 Bn | 78.30 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 65.17 Bn | 59.98 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 61.38 Bn | 56.24 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 42.18 Bn | 37.09 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.99 Bn | 27.68 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.45 Bn | 10.05 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 630.93 Mn |
| 10 | Citius Pharmaceuticals | 15.81 Mn | 15.81 Mn | 1.00 Mn | 51.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 55.02 Mn |
| Dec 31, 2025 | 38.21 Mn |
| Sep 30, 2025 | 44.91 Mn |
| Jun 30, 2025 | 51.84 Mn |
| Mar 31, 2025 | 49.88 Mn |
| Dec 31, 2024 | 44.81 Mn |
| Sep 30, 2024 | 35.81 Mn |
| Jun 30, 2024 | 4.15 Mn |
| Mar 31, 2024 | 4.17 Mn |
| Dec 31, 2023 | 5.58 Mn |
| Sep 30, 2023 | 5.78 Mn |
| Jun 30, 2023 | 5.79 Mn |
| Mar 31, 2023 | 6.21 Mn |
| Dec 31, 2022 | 4.54 Mn |
| Sep 30, 2022 | 4.53 Mn |
| Jun 30, 2022 | 4.46 Mn |
| Mar 31, 2022 | 4.02 Mn |
| Dec 31, 2021 | 7.34 Mn |
| Sep 30, 2021 | 3.98 Mn |
| Jun 30, 2021 | 3.60 Mn |